Thymosin Alpha-1 (TA1) is a synthetic 28–amino acid peptide originally isolated from thymus tissue. It is known for its potent immunomodulatory properties, enhancing both innate and adaptive immune responses. TA1 works by activating T-cells, modulating cytokine production, and increasing the activity of dendritic cells and natural killer (NK) cells. It has been studied in infectious disease, cancer, and immune deficiency research. Thymosin Alpha-1 is approved for medical use in some countries (such as China and Italy) but remains experimental and is not FDA-approved in the United States.
How It Is Used in Research Settings
- Studied for enhancing immune response in chronic infections, including hepatitis B and C.
- Explored as an immune adjuvant in cancer immunotherapy research.
- Investigated in sepsis and critical illness for immune regulation.
- Examined for its potential role in vaccine enhancement and immune resilience.
Proposed Uses (Research Areas)
- Infectious disease research (viral, bacterial, and fungal).
- Cancer immunotherapy and immune regulation models.
- Autoimmune and immunodeficiency studies.
- Vaccine adjuvant research.
How It Is Dosed in Research Settings
- Injectable (Subcutaneous or Intramuscular): Research doses commonly range from 1.6–3.2 mg, administered 2–3 times per week.
- Cycle length: Clinical and experimental protocols often last 4–6 weeks, with some extended for months in chronic infection or cancer studies.
- Handling: Supplied as lyophilized powder; reconstituted with sterile water and stored refrigerated.
Important Considerations
- Regulatory status: Approved in some countries for immune-related conditions but not FDA-approved in the United States.
- Evidence base: Clinical studies support its role in enhancing immune function, particularly in chronic viral infections and oncology. Broader validation is ongoing.
- Safety: Generally well tolerated in trials, with reported side effects including mild injection site reactions, fatigue, or flu-like symptoms. Long-term safety is still under study.
Disclaimer
This material is provided for educational purposes only and summarizes published research on Thymosin Alpha-1 (TA1).
It is not medical advice. TA1 is experimental, not FDA-approved in the United States, and should not be viewed as a therapy for medical use.
This peptide is for research use only.